Literature DB >> 15103880

The prescribing and follow-up of domiciliary oxygen--whose responsibility? A survey of prescribing from primary care.

A Pali Hungin1, David J Chinn, Bernie Convery, Charles Dean, Charles S Cornford, Andrew Russell.   

Abstract

Domiciliary oxygen is expensive and is frequently used outside the prescribing guidelines, which include the need for blood oxygen measures, a hospital-based facility. Ongoing prescriptions are generally provided by general practitioners (GPs). A survey in the north-east of England found that the origin of the initial prescription was often obscure and that there was no record of the responsible clinician or of structured follow-up for the majority of patients. Many patients received oxygen outside the prescribing guidelines. There is a need for better organised, conjoint follow-up of patients on domiciliary oxygen.

Entities:  

Mesh:

Year:  2003        PMID: 15103880      PMCID: PMC1314695     

Source DB:  PubMed          Journal:  Br J Gen Pract        ISSN: 0960-1643            Impact factor:   5.386


  5 in total

1.  Audit on prescription of long-term oxygen treatment.

Authors:  P Shankar; M M Muthiah
Journal:  Clin Perform Qual Health Care       Date:  2000

2.  Implementation of an oxygen therapy clinic to manage users of long-term oxygen therapy.

Authors:  John C Chaney; Kevin Jones; Kurt Grathwohl; Kenneth N Olivier
Journal:  Chest       Date:  2002-11       Impact factor: 9.410

3.  Impact of a hospital-based home-care program on the management of COPD patients receiving long-term oxygen therapy.

Authors:  E Farrero; J Escarrabill; E Prats; M Maderal; F Manresa
Journal:  Chest       Date:  2001-02       Impact factor: 9.410

4.  Prescription of oxygen concentrators for long term oxygen treatment: reassessment in one district.

Authors:  M J Walshaw; R Lim; C C Evans; C R Hind
Journal:  BMJ       Date:  1988-10-22

5.  Review of the prescription of domiciliary long term oxygen therapy in Scotland.

Authors:  D Morrison; K Skwarski; W MacNee
Journal:  Thorax       Date:  1995-10       Impact factor: 9.139

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.